LY3090106 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome
Trial Timeline
Dec 10, 2015 → Sep 5, 2018
NCT ID
NCT02614716About LY3090106 + Placebo
LY3090106 + Placebo is a phase 1 stage product being developed by Eli Lilly for Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02614716. Target conditions include Sjögren's Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03736772 | Phase 1 | Completed |
| NCT02614716 | Phase 1 | Completed |
Competing Products
20 competing products in Sjögren's Syndrome